142 related articles for article (PubMed ID: 37992152)
1. Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency.
Altarejos JY; Pangilinan J; Podgrabinska S; Akinci B; Foss-Freitas M; Neidert AH; Ray Y; Zheng W; Kim S; Kamat V; Huang M; Min S; Mastaitis J; Dominguez-Gutierrez G; Kim JH; Stevis P; Huang T; Zambrowicz B; Olson WC; Godin S; Bradley E; Gewitz AD; Baker M; Hench R; Davenport MS; Chenevert TL; DiPaola F; Yancopoulos GD; Murphy AJ; Herman GA; Musser BJ; Dansky H; Harp J; Gromada J; Sleeman MW; Oral EA; Olenchock BA
Sci Transl Med; 2023 Nov; 15(723):eadd4897. PubMed ID: 37992152
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first-in-human phase I study.
Gewitz A; Mendell J; Wang Y; Harris C; Olenchock BA; Podgrabinska S; Zheng W; Zhao A; Pan H; Vanhoutte F; Davis JD
Clin Transl Sci; 2024 Apr; 17(4):e13762. PubMed ID: 38591811
[TBL] [Abstract][Full Text] [Related]
3. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA
Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649
[TBL] [Abstract][Full Text] [Related]
4. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
[TBL] [Abstract][Full Text] [Related]
5. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
[TBL] [Abstract][Full Text] [Related]
6. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
Tchang BG; Shukla AP; Aronne LJ
Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
Chan JL; Koda J; Heilig JS; Cochran EK; Gorden P; Oral EA; Brown RJ
Clin Endocrinol (Oxf); 2016 Jul; 85(1):137-49. PubMed ID: 26589105
[TBL] [Abstract][Full Text] [Related]
8. Treatment Options for Lipodystrophy in Children.
Mainieri F; Tagi VM; Chiarelli F
Front Endocrinol (Lausanne); 2022; 13():879979. PubMed ID: 35600578
[TBL] [Abstract][Full Text] [Related]
9. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T; Cochran E; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
[TBL] [Abstract][Full Text] [Related]
10. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals.
Moon HS; Dalamaga M; Kim SY; Polyzos SA; Hamnvik OP; Magkos F; Paruthi J; Mantzoros CS
Endocr Rev; 2013 Jun; 34(3):377-412. PubMed ID: 23475416
[TBL] [Abstract][Full Text] [Related]
11. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P
Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
[TBL] [Abstract][Full Text] [Related]
13. A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles.
Fukaishi T; Minami I; Masuda S; Miyachi Y; Tsujimoto K; Izumiyama H; Hashimoto K; Yoshida M; Takahashi S; Kashimada K; Morio T; Kosaki K; Maezawa Y; Yokote K; Yoshimoto T; Yamada T
Endocr J; 2020 Feb; 67(2):211-218. PubMed ID: 31708526
[TBL] [Abstract][Full Text] [Related]
14. An allosteric antibody to the leptin receptor reduces body weight and reverses the diabetic phenotype in the Lep(ob) /Lep(ob) mouse.
Bhaskar V; Goldfine ID; Gerstner R; Michelson K; Tran C; Nonet G; Bohmann D; Pongo E; Zhao J; Horwitz AH; Takeuchi T; White M; Corbin JA
Obesity (Silver Spring); 2016 Aug; 24(8):1687-94. PubMed ID: 27330016
[TBL] [Abstract][Full Text] [Related]
15. Inter-organ insulin-leptin signal crosstalk from the liver enhances survival during food shortages.
Takahashi K; Yamada T; Hosaka S; Kaneko K; Asai Y; Munakata Y; Seike J; Horiuchi T; Kodama S; Izumi T; Sawada S; Hoshikawa K; Inoue J; Masamune A; Ueno Y; Imai J; Katagiri H
Cell Rep; 2023 May; 42(5):112415. PubMed ID: 37116488
[TBL] [Abstract][Full Text] [Related]
16. Partial leptin deficiency confers resistance to diet-induced obesity in mice.
Zhao S; Li N; Zhu Y; Straub L; Zhang Z; Wang MY; Zhu Q; Kusminski CM; Elmquist JK; Scherer PE
Mol Metab; 2020 Jul; 37():100995. PubMed ID: 32289482
[TBL] [Abstract][Full Text] [Related]
17. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895
[TBL] [Abstract][Full Text] [Related]
18. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.
Mulligan K; Khatami H; Schwarz JM; Sakkas GK; DePaoli AM; Tai VW; Wen MJ; Lee GA; Grunfeld C; Schambelan M
J Clin Endocrinol Metab; 2009 Apr; 94(4):1137-44. PubMed ID: 19174500
[TBL] [Abstract][Full Text] [Related]
19. New advances in the treatment of generalized lipodystrophy: role of metreleptin.
Rodriguez AJ; Mastronardi CA; Paz-Filho GJ
Ther Clin Risk Manag; 2015; 11():1391-400. PubMed ID: 26396524
[TBL] [Abstract][Full Text] [Related]
20. Reduced Endothelial Leptin Signaling Increases Vascular Adrenergic Reactivity in a Mouse Model of Congenital Generalized Lipodystrophy.
Bruder-Nascimento T; Kress TC; Pearson M; Chen W; Kennard S; Belin de Chantemèle EJ
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
